Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DNK101
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DNK101 is an investigational, allogeneic, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech. It is engineered to express CARs that simultaneously target two tumor-associated antigens: Mesothelin (MSLN) and Mucin 1 (MUC1). This dual-targeting approach is designed to enhance tumor recognition and mitigate the risk of antigen escape, which is a common challenge in treating solid tumors like pancreatic cancer. As an allogeneic therapy, EB-DNK101 is intended to be an "off-the-shelf" product, potentially offering faster access and lower costs compared to autologous cell therapies. It is currently in Phase 1/2 clinical development for patients with unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC).
- Other names
- EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
02
Targets
Mesothelin
Beyond the preview
Go deeper on EB-DNK101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DNK101.